130 related articles for article (PubMed ID: 29135538)
41. History, development and future of cancer screening in Australia.
Olver IN; Roder D
Public Health Res Pract; 2017 Jul; 27(3):. PubMed ID: 28765858
[TBL] [Abstract][Full Text] [Related]
42. [Interval between two smear tests for cervical cancer screening and characteristics of women with a short interval: Study in the department of Isère].
Caporossi A; Olicard C; Seigneurin A; Garnier A
Rev Epidemiol Sante Publique; 2019 May; 67(3):143-147. PubMed ID: 30981595
[TBL] [Abstract][Full Text] [Related]
43. How will transitioning from cytology to HPV testing change the balance between the benefits and harms of cervical cancer screening? Estimates of the impact on cervical cancer, treatment rates and adverse obstetric outcomes in Australia, a high vaccination coverage country.
Velentzis LS; Caruana M; Simms KT; Lew JB; Shi JF; Saville M; Smith MA; Lord SJ; Tan J; Bateson D; Quinn M; Canfell K
Int J Cancer; 2017 Dec; 141(12):2410-2422. PubMed ID: 28801947
[TBL] [Abstract][Full Text] [Related]
44. Impact of the Australian National Cervical Screening Program in women of different ages.
Smith M; Canfell K
Med J Aust; 2016 Oct; 205(8):359-364. PubMed ID: 27736623
[TBL] [Abstract][Full Text] [Related]
45. The combined impact of implementing HPV immunisation and primary HPV screening in New Zealand: Transitional and long-term benefits, costs and resource utilisation implications.
Hall MT; Smith MA; Lew JB; O'Hallahan J; Fentiman G; Neal H; Sage M; Canfell K
Gynecol Oncol; 2019 Mar; 152(3):472-479. PubMed ID: 30876491
[TBL] [Abstract][Full Text] [Related]
46. National Cervical Cancer Screening in Thailand.
Ploysawang P; Rojanamatin J; Prapakorn S; Jamsri P; Pangmuang P; Seeda K; Sangrajrang S
Asian Pac J Cancer Prev; 2021 Jan; 22(1):25-30. PubMed ID: 33507675
[TBL] [Abstract][Full Text] [Related]
47. Cervical cancer screening coverage in a high-incidence region.
Navarro C; Fonseca AJ; Sibajev A; Souza CI; Araújo DS; Teles DA; Carvalho SG; Cavalcante KW; Rabelo WL
Rev Saude Publica; 2015; 49():17. PubMed ID: 25741655
[TBL] [Abstract][Full Text] [Related]
48. [Attendance rate in the Polish Cervical Cancer Screening Program in the years 2007-2009].
Spaczyński M; Karowicz-Bilinska A; Rokita W; Molińska-Glura M; Januszek-Michalecka L; Seroczyński P; Uchlik J; Nowak-Markwitz E
Ginekol Pol; 2010 Sep; 81(9):655-63. PubMed ID: 20973201
[TBL] [Abstract][Full Text] [Related]
49. Temporal changes in the cervical cancer burden in Bulgaria: Implications for eastern european countries going through transition.
Samson KK; Haynatzki G; Soliman AS; Valerianova Z
Cancer Epidemiol; 2016 Oct; 44():154-160. PubMed ID: 27597149
[TBL] [Abstract][Full Text] [Related]
50. Cervical cancer screening in Serbia.
Kesić V; Jovićević-Bekić A; Vujnović M
Coll Antropol; 2007 Apr; 31 Suppl 2():31-6. PubMed ID: 17598502
[TBL] [Abstract][Full Text] [Related]
51. Cervical cancer prevention in Australia: Planning for the future.
Saville AM
Cancer Cytopathol; 2016 Apr; 124(4):235-40. PubMed ID: 26619381
[TBL] [Abstract][Full Text] [Related]
52. The impact of a two- versus three-yearly cervical screening interval recommendation on cervical cancer incidence and mortality: an analysis of trends in Australia, New Zealand, and England.
Simonella L; Canfell K
Cancer Causes Control; 2013 Sep; 24(9):1727-36. PubMed ID: 23832659
[TBL] [Abstract][Full Text] [Related]
53. [Cervical cancer screening in Germany].
Bujan Rivera J; Klug SJ
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2018 Dec; 61(12):1528-1535. PubMed ID: 30397722
[TBL] [Abstract][Full Text] [Related]
54. Cervical Cancer Screening: Recommendations for Muslim Societies.
Khodakarami N; Farzaneh F; Yavari P; Akbari ME
Asian Pac J Cancer Prev; 2016; 17(1):239-47. PubMed ID: 26838217
[TBL] [Abstract][Full Text] [Related]
55. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia.
Berkhof J; Bogaards JA; Demirel E; Diaz M; Sharma M; Kim JJ
Vaccine; 2013 Dec; 31 Suppl 7():H71-9. PubMed ID: 24332299
[TBL] [Abstract][Full Text] [Related]
56. Human papillomavirus infection and cervical cancer prevention in Japan and Korea.
Konno R; Shin HR; Kim YT; Song YS; Sasagawa T; Inoue M; Park JS
Vaccine; 2008 Aug; 26 Suppl 12():M30-42. PubMed ID: 18945412
[TBL] [Abstract][Full Text] [Related]
57. National cervical cancer prevention program in the Arab States: Strategies and cost-minimization study of the Tunisian case.
Gamaoun R
Vaccine; 2018 Aug; 36(33):5091-5096. PubMed ID: 29983258
[TBL] [Abstract][Full Text] [Related]
58. Cervical cancer epidemiology in Friuli Venezia Giulia.
Vicario G; French S; Little D; Forgiarini O; Bidoli E; Zanier L; Franceschi S
Tumori; 2002; 88(6):457-60. PubMed ID: 12597137
[TBL] [Abstract][Full Text] [Related]
59. Factors associated with participation in the organized cervical cancer screening program in the greater Paris area (France): An analysis among more than 200,000 women.
Audiger C; Bovagnet T; Deghaye M; Kaufmanis A; Pelisson C; Bochaton A; Menvielle G
Prev Med; 2021 Dec; 153():106831. PubMed ID: 34624389
[TBL] [Abstract][Full Text] [Related]
60. A population-based combination strategy to improve the cervical cancer screening coverage rate in Bamako, Mali.
Téguété I; Tounkara FK; Diawara B; Traoré S; Koné D; Bagayogo A; Sissoko A; Traoré CB
Acta Obstet Gynecol Scand; 2021 Apr; 100(4):794-801. PubMed ID: 33560520
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
